We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    02029573
Previous Study | Return to List | Next Study

Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma (ART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02029573
Recruitment Status : Completed
First Posted : January 8, 2014
Last Update Posted : August 18, 2017
Information provided by (Responsible Party):
Abdullah Khalaf Altwairgi, King Fahad Medical City

Brief Summary:
The purpose of this study is to explore the efficacy and safety of Atorvastatin in combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).The anticipated time on study treatment is until disease progression, and the target sample size is 32 individuals.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Atorvastatin Drug: Temozolomide Radiation: Radiotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma
Actual Study Start Date : January 1, 2014
Actual Primary Completion Date : December 31, 2016
Actual Study Completion Date : December 31, 2016

Arm Intervention/treatment
Experimental: Atorvastatin in Combination With Radiotherapy and Temozolomide Drug: Atorvastatin
80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)

Drug: Temozolomide
75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy

Radiation: Radiotherapy
60 Gy in 30 fractions

Primary Outcome Measures :
  1. Progression free survival at 6 months (PFS-6) [ Time Frame: up to 6 months ]
    All efficacy determinations will be based on the Response Assessment in Neuro-Oncology (RANO) response criteria (Wen 2010)

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Up to 2-3 years ]
    Progression free survival defined as the time the patient enters the study until first progression or death whichever occurs first

  2. Overall Survival (OS) [ Time Frame: Up to 2-3 years ]
    Overall Survival defined as the time the patient enters the study to the date of death due to any cause.

  3. Adverse events [ Time Frame: Up to 2-3 years ]
    The assessment of safety will be based on the frequency of Adverse Events graded (grade 3+) according to the Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 scoring system.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven newly diagnosed Malignant Glioblastoma Multiforme or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma).
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
  • Patients must have an estimated life expectancy of at least 12 weeks.
  • No prior chemotherapy or radiotherapy.
  • Stable dose of steroid for ≥ 14 days prior to registration.
  • Patients must have adequate bone marrow function (e.g., hemoglobin ≥10 g/dl, absolute granulocyte count ≥ 1.5 x 109/L, and platelet count ≥100 x 109/L.
  • Adequate liver function (SGPT, SGOT, and alkaline phosphatase ≤ 2.5 times upper limits of normals (ULN) and total bilirubin ≤1.5 x ULN), and adequate renal function (BUN or creatinine ≤1.5 X ULN) prior to starting therapy.
  • Paraffin embedded tumour sample available for study.
  • Patient consent must be obtained according to local Institutional requirements. The patient must sign the consent form prior to registration.
  • Protocol treatment is to begin within 10 working days of patient registration.

Exclusion Criteria:

  • Pregnant or lactating women; men and women of childbearing potential must agree to practice an effective method of birth control. Women of childbearing potential must have a negative pregnancy test performed within 14 days prior to registration.
  • Concurrent treatment with other experimental drugs or anticancer therapy.
  • Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years.
  • Prior radiotherapy or systemic cytotoxic chemotherapy .
  • Severe, active co-morbidity, defined as follows: Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration, Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or oxygen, Hepatic insufficiency or Active liver disease resulting in clinical jaundice and/or coagulation defects, Acquired immune deficiency syndrome (AIDS) , Significant neurologic or psychiatric disorder which would impair the ability to obtain informed consent, Active uncontrolled or serious infection, active peptic ulcer disease, Any medical condition which could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction), Myocardial infarction within 6 months prior to registration, Congestive heart failure, unstable angina, active cardiomyopathy, cardiac arrhythmia, Skeletal muscle disease and other related reticule-endothelial diseases.
  • Patients with known hypersensitivity to the study drugs or their components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02029573

Layout table for location information
Saudi Arabia
King Fahad Medical City
Riyadh, Saudi Arabia, 11525
Sponsors and Collaborators
King Fahad Medical City
Layout table for investigator information
Study Chair: Abdullah K. Altwairgi, MD King Fahad Medical City
Additional Information:
Layout table for additonal information
Responsible Party: Abdullah Khalaf Altwairgi, Medical Oncologist, King Fahad Medical City
ClinicalTrials.gov Identifier: NCT02029573    
Other Study ID Numbers: KFMC-CNS-01
First Posted: January 8, 2014    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Keywords provided by Abdullah Khalaf Altwairgi, King Fahad Medical City:
Phase II
Glioblastoma Multiforme (GBM)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Antineoplastic Agents